Novartis to Acquire Avidity Biosciences for $12 Billion
Novartis will acquire Avidity Biosciences for approximately $12 billion in cash, announced in a press release. Under the terms of the agreement, Avidity shareholders will receive $72.00 per share, representing a 46% premium over Avidity’s October 24, 2025 closing price.
The acquisition, unanimously approved by both companies’ boards, is expected to close in the first half of 2026, subject to regulatory and shareholder approvals. Completion is also contingent on the separation of Avidity’s early-stage precision cardiology programs into a new publicly traded company, SpinCo.
SpinCo will be led by Kathleen Gallagher, currently Avidity’s chief program officer, as chief executive officer, with Avidity CEO Sarah Boyce serving as chair of the board. The new entity will focus on programs targeting rare genetic cardiomyopathies, including AOC 1086 and AOC 1072.
Through the acquisition, Novartis will gain Avidity’s neuroscience programs and its RNA-targeting delivery platform, including three late-stage clinical programs for Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 19 Knit Health raises $35 million to roll out its healthcare world model Nov 19 Banner Health invests in Layer Health and moves its clinical registries onto its AI platform Nov 19 Half of Koreans who changed medication on AI advice had side effects, survey finds Nov 19 Isomorphic Labs and MSD team up to design cancer drugs with AI Nov 19 Boltz raises $110 million to build AI models for drug designMore from Funding
Nov 20 hackajob raises $10 million to expand Archer, its AI recruiting agent Nov 20 Protesters rally against Anthropic in New York and San Francisco on its stock market debut Nov 19 Anthropic's IPO could channel about $156 billion to charity, TechCrunch estimates Nov 19 Sierra reportedly in talks to raise at a $30 billion valuation Nov 19 Everful raises $48.5 million to build AI infrastructure for global commerceAI Funding Brief
Humanoid Robot Makers
Companies building humanoid robots, from startups to Tesla and Boston Dynamics
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
Atlas Bio raises $12.5 million for virtual drug trials
Isomorphic Labs and MSD team up to design cancer drugs with AI
Astromech acquires Form Bio in $230 million all-stock deal
Pathos AI Raises $237 Million at $3 Billion Valuation
Agility Robotics Expects $465 Million Raise as SPAC Merger Nears Close
Daily AI Brief: the AI news that matters, in your inbox.